Collaborating for Better R&D Productivity
Executive Summary
Pooling multiple pharmaceutical companies' assets across a given therapeutic area will allow industry to make rational R&D investment decisions, expedite resource allocation and reduce investment in also-rans, eventually boosting productivity and improving a worsening reimbursement environment. Oncology may be a smart place to begin.
You may also be interested in...
In A First, Merck And AstraZeneca Team Up For Oncology Study
The two Big Pharmas have allied for early development of Merck’s AKT inhibitor and AZ’s Mek inhibitor. But where do they go from there?
Best of the Blog: IN VIVO, May/June 2009
Our favorite blog posts related to stories not covered elsewhere in this month's IN VIVO.
Best of the Blog: IN VIVO, May/June 2009
Our favorite blog posts related to stories not covered elsewhere in this month's IN VIVO.